Who is sponsoring NCT07114666?

NCT07114666 is sponsored by Peking Union Medical College Hospital.

What condition does NCT07114666 study?

NCT07114666 studies Pancreatic Cancer.

What drugs are being tested in NCT07114666?

Interventions: XH001, Chemotherapy.

What is the status of NCT07114666?

NCT07114666 is currently NOT_YET_RECRUITING.

Last reviewed 2025-08-08 · How we verify

Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients

NCT07114666 NA NOT_YET_RECRUITING

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer patients following surgical resection.

Details

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	12
Start date	2025-08-18
Completion	2030-08

Conditions

Pancreatic Cancer

Interventions

XH001
Chemotherapy

Primary outcomes

DFS — From operation up to 36 months
Disease Free Survival
DFS Rate — 12,24 and 36 months
Disease-free survival rate
MFS — up to 36 months
metastasis-free survival
OS — up to 48 months
Overall survival

Countries

China